On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...

People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...

Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...

The US Food and Drug Administration (FDA ... About one in 300 people worldwide are affected by schizophrenia, but for decades treatment options have been both static and limited.

In response to the recent flooding in Maiduguri, Borno State, the National Agency for Food and Drug Administration and Control (NAFDAC) has said it conducted a mop-up operation and removed ...

The National Agency for Food and Drug Administration and Control has conducted a comprehensive mop-up operation across various markets in Maiduguri, Borno State. A press statement signed by the ...

A source of the parasites has not yet been found. The Food and Drug Administration first reported the outbreak on Aug. 7 and the patient count has steadily… A Codex committee has made progress ...

according to a recall issued by the U.S. Food & Drug Administration. Those with an allergy or severe sensitivity to almonds could run the risk of serious or life-threatening allergic reactions if ...